Literature DB >> 9660853

(R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6.

S C Khojasteh-Bakht1, L L Koenigs, R M Peter, W F Trager, S D Nelson.   

Abstract

(R)-(+)-Menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 (CYP or P450) 2A6. Menthofuran caused a time- and concentration-dependent loss of CYP2A6 activity. The inactivation of CYP2A6 was characterized by a Ki of 2.5 microM and a kinact of 0.22 min-1 for human liver microsomes and a Ki of 0.84 microM and a kinact of 0.25 min-1 for purified expressed CYP2A6. Addition of various nucleophiles, a chelator of iron, or scavengers of reactive oxygen species or extensive dialysis failed to protect CYP2A6 from inactivation. An antibody to metallothionein conjugates of a suspected reactive metabolite of menthofuran was used to detect reactive menthofuran metabolite adducts with CYP2A6. These adducts were formed only in the presence of NADPH-P450 reductase and NADPH. Glutathione, methoxylamine, and semicarbazide did not prevent adduction of reactive menthofuran metabolites to CYP2A6, however. The menthofuran metabolite formation/CYP2A6 inactivation partition ratio was determined to be 3.5 +/- 0.6 nmol/nmol of P450. Menthofuran was unable to inactivate CYP1A2, CYP2D6, CYP2E1, or CYP3A4 in a time- and concentration-dependent manner.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660853

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.

Authors:  K Ohyama; M Nakajima; M Suzuki; N Shimada; H Yamazaki; T Yokoi
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

3.  Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole.

Authors:  Jeannine Chan; Tyler Oshiro; Sarah Thomas; Allyson Higa; Stephen Black; Aleksandar Todorovic; Fawzy Elbarbry; John P Harrelson
Journal:  Drug Metab Dispos       Date:  2016-02-05       Impact factor: 3.922

4.  Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol.

Authors:  Valerie M Kramlinger; Linda B von Weymarn; Sharon E Murphy
Journal:  Chem Biol Interact       Date:  2012-04-01       Impact factor: 5.192

5.  Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.

Authors:  Eva S Stephens; Agnes A Walsh; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2012-06-13       Impact factor: 3.922

Review 6.  Reactive metabolites in the biotransformation of molecules containing a furan ring.

Authors:  Lisa A Peterson
Journal:  Chem Res Toxicol       Date:  2012-10-24       Impact factor: 3.739

Review 7.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  Safety and efficacy of a feed additive consisting of an essential oil from the leaves of Agathosma betulina (P.J. Bergius) Pillans (buchu leaf oil) for use in all animal species (FEFANA asbl).

Authors:  Vasileios Bampidis; Giovanna Azimonti; Maria de Lourdes Bastos; Henrik Christensen; Mojca Fašmon Durjava; Maryline Kouba; Marta López-Alonso; Secundino López Puente; Francesca Marcon; Baltasar Mayo; Alena Pechová; Mariana Petkova; Fernando Ramos; Yolanda Sanz; Roberto Edoardo Villa; Ruud Woutersen; Paul Brantom; Andrew Chesson; Johannes Westendorf; Paola Manini; Fabiola Pizzo; Birgit Dusemund
Journal:  EFSA J       Date:  2022-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.